Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 14, 2023 07:00 ET
|
Larimar Therapeutics
Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious...
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
November 01, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
October 03, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
August 31, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 10, 2023 07:00 ET
|
Larimar Therapeutics
Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension...
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
July 25, 2023 07:00 ET
|
Larimar Therapeutics
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing...
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
July 17, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Set to Join Russell 3000® Index
June 21, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
May 15, 2023 07:00 ET
|
Larimar Therapeutics
Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28Daily...
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
March 28, 2023 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...